NCT01015300View on ClinicalTrials.gov

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

October 31, 2011

Study Completion Date

April 30, 2012

Conditions
HemangioblastomasVon Hippel Lindau Disease
Interventions
DRUG

Avastin

Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months

Trial Locations (1)

03756

Dartmouth Hitchcock Medical Center, Lebanon

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT01015300 - Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease | Biotech Hunter | Biotech Hunter